- Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
- Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
- Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
- Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
- Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
- Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
- Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Thursday, Annexon Inc (ANNX:NSQ) closed at 7.17, -14.64% below its 52-week high of 8.40, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.00 |
---|---|
High | 8.26 |
Low | 7.03 |
Bid | 7.30 |
Offer | 7.45 |
Previous close | 7.81 |
Average volume | 3.35m |
---|---|
Shares outstanding | 90.03m |
Free float | 70.48m |
P/E (TTM) | -- |
Market cap | 645.48m USD |
EPS (TTM) | -1.78 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼